vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Genius Sports Ltd (GENI). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($749.2M vs $510.9M, roughly 1.5× Genius Sports Ltd). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — 3.6% vs -12.3%, a 16.0% gap on every dollar of revenue. Over the past eight quarters, Genius Sports Ltd's revenue compounded faster (129.2% CAGR vs 45.0%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Genius Sports is a sports data and technology company that provides data management, video streaming and integrity services to sports leagues, bookmakers and media companies.

CLOV vs GENI — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.5× larger
CLOV
$749.2M
$510.9M
GENI
Higher net margin
CLOV
CLOV
16.0% more per $
CLOV
3.6%
-12.3%
GENI
Faster 2-yr revenue CAGR
GENI
GENI
Annualised
GENI
129.2%
45.0%
CLOV

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CLOV
CLOV
GENI
GENI
Revenue
$749.2M
$510.9M
Net Profit
$27.3M
$-63.0M
Gross Margin
25.2%
Operating Margin
3.6%
-11.5%
Net Margin
3.6%
-12.3%
Revenue YoY
62.0%
Net Profit YoY
EPS (diluted)
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
GENI
GENI
Q1 26
$749.2M
Q4 25
$487.7M
$510.9M
Q3 25
$496.6M
$335.4M
Q2 25
$477.6M
$215.2M
Q1 25
$462.3M
$119.7M
Q4 24
$337.0M
$413.0M
Q3 24
$331.0M
$285.8M
Q2 24
$356.3M
$184.1M
Net Profit
CLOV
CLOV
GENI
GENI
Q1 26
$27.3M
Q4 25
$-49.3M
$-63.0M
Q3 25
$-24.4M
Q2 25
$-10.6M
$-47.3M
Q1 25
$-1.3M
$-25.5M
Q4 24
$-22.1M
$-85.5M
Q3 24
$-9.2M
$-47.1M
Q2 24
$7.4M
$-35.5M
Gross Margin
CLOV
CLOV
GENI
GENI
Q1 26
Q4 25
25.2%
Q3 25
24.2%
Q2 25
19.1%
Q1 25
10.7%
Q4 24
16.7%
Q3 24
24.5%
20.5%
Q2 24
30.3%
18.6%
Operating Margin
CLOV
CLOV
GENI
GENI
Q1 26
3.6%
Q4 25
-10.1%
-11.5%
Q3 25
-4.9%
-15.3%
Q2 25
-2.2%
-21.0%
Q1 25
-0.3%
-20.3%
Q4 24
-6.4%
-18.0%
Q3 24
-2.7%
-13.9%
Q2 24
2.0%
-16.8%
Net Margin
CLOV
CLOV
GENI
GENI
Q1 26
3.6%
Q4 25
-10.1%
-12.3%
Q3 25
-4.9%
Q2 25
-2.2%
-22.0%
Q1 25
-0.3%
-21.3%
Q4 24
-6.6%
-20.7%
Q3 24
-2.8%
-16.5%
Q2 24
2.1%
-19.3%
EPS (diluted)
CLOV
CLOV
GENI
GENI
Q1 26
$0.05
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
GENI
GENI
Cash + ST InvestmentsLiquidity on hand
$177.6M
$280.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$339.4M
$724.5M
Total Assets
$697.7M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
GENI
GENI
Q1 26
$177.6M
Q4 25
$78.3M
$280.6M
Q3 25
$110.2M
Q2 25
$110.2M
Q1 25
$110.2M
Q4 24
$194.5M
$100.3M
Q3 24
$288.0M
$100.3M
Q2 24
$254.8M
$100.3M
Stockholders' Equity
CLOV
CLOV
GENI
GENI
Q1 26
$339.4M
Q4 25
$308.7M
$724.5M
Q3 25
$340.9M
$572.4M
Q2 25
$344.2M
$572.4M
Q1 25
$336.1M
$572.4M
Q4 24
$341.1M
$573.0M
Q3 24
$342.2M
$573.0M
Q2 24
$324.9M
$573.0M
Total Assets
CLOV
CLOV
GENI
GENI
Q1 26
$697.7M
Q4 25
$541.0M
$1.1B
Q3 25
$559.7M
$792.3M
Q2 25
$575.0M
$792.3M
Q1 25
$583.7M
$792.3M
Q4 24
$580.7M
$775.7M
Q3 24
$653.0M
$775.7M
Q2 24
$674.2M
$775.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
GENI
GENI
Operating Cash FlowLast quarter
$81.9M
Free Cash FlowOCF − Capex
$69.6M
FCF MarginFCF / Revenue
13.6%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$33.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
GENI
GENI
Q1 26
Q4 25
$-66.9M
$81.9M
Q3 25
$12.1M
$-4.8M
Q2 25
$5.4M
$-1.2M
Q1 25
$-16.3M
$-14.6M
Q4 24
$34.8M
$14.9M
Q3 24
$50.0M
$-9.2M
Q2 24
$44.8M
Free Cash Flow
CLOV
CLOV
GENI
GENI
Q1 26
Q4 25
$-69.0M
$69.6M
Q3 25
$11.4M
$-14.2M
Q2 25
$4.8M
$-5.8M
Q1 25
$-16.5M
$-16.0M
Q4 24
$33.3M
$11.3M
Q3 24
$49.6M
$-11.6M
Q2 24
$44.4M
FCF Margin
CLOV
CLOV
GENI
GENI
Q1 26
Q4 25
-14.1%
13.6%
Q3 25
2.3%
-4.2%
Q2 25
1.0%
-2.7%
Q1 25
-3.6%
-13.4%
Q4 24
9.9%
2.7%
Q3 24
15.0%
-4.1%
Q2 24
12.5%
Capex Intensity
CLOV
CLOV
GENI
GENI
Q1 26
Q4 25
0.4%
2.4%
Q3 25
0.1%
2.8%
Q2 25
0.1%
2.1%
Q1 25
0.0%
1.2%
Q4 24
0.5%
0.9%
Q3 24
0.1%
0.9%
Q2 24
0.1%
Cash Conversion
CLOV
CLOV
GENI
GENI
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
6.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons